Skin Barrier Abnormalities and Oxidative Stress Response

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359 ·Status: ACTIVE_NOT_RECRUITING

Sodium in the Skin and Atopic Dermatitis

NCT06998446 ·Status: RECRUITING

Frequency of Food Allergy Confirm by Oral Food Challenge Among Foods Avoidance in Atopic Dermatitis Children

NCT06947252 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up

NCT00795496 ·Status: COMPLETED

Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels

NCT00616096 ·Status: COMPLETED ·Phase: NA

Short-term Topical Application to Prevent Atopic Dermatitis

NCT03871998 ·Status: COMPLETED ·Phase: NA

Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

NCT05098821 ·Status: RECRUITING

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

NCT04556461 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

NCT00557284 ·Status: COMPLETED ·Phase: PHASE4

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

NCT05602207 ·Status: COMPLETED ·Phase: PHASE4

Immune Response to Varicella Vaccination in Children With Atopic Dermatitis

NCT00406081 ·Status: COMPLETED

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03864627 ·Status: TERMINATED ·Phase: PHASE2

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

NCT04256174 ·Status: COMPLETED ·Phase: PHASE1

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893 ·Status: TERMINATED ·Phase: PHASE4

Systems Biology of Early Atopy

NCT04798079 ·Status: ACTIVE_NOT_RECRUITING

Dietary Intervention on Atopy

NCT06547372 ·Status: RECRUITING ·Phase: NA

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

NCT03257644 ·Status: COMPLETED ·Phase: PHASE1

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

NCT04455906 ·Status: RECRUITING

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605 ·Status: RECRUITING

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

NCT06039241 ·Status: RECRUITING

Effects of Abrocitinib Treatment on Skin Barrier Function

NCT05140239 ·Status: ACTIVE_NOT_RECRUITING

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

NCT03689829 ·Status: TERMINATED ·Phase: PHASE1

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803 ·Status: RECRUITING

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

NCT03646604 ·Status: COMPLETED ·Phase: PHASE1

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

NCT05983068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4